Summarv To assess the role of hepatitis B e antizen (HBeAg) 
. Persistent hepatitis B virus (HBV) infection has been clearly implicated in the development of HCC : Chen. 1993 Tsai et al.. 1994a-f) . Do all HBsAg carriers haxe an equal chance of dexeloping HCC. and x-hat factors can be used clinically to select patients for intensixve screening and periodic folloxw-up examination?
Hepatitis B e antigen (HBeAg) is a protein of 159 amino acids encoded by the preC region and the C gene of HBV (Gupta and Shafritz. 1994: Thomas and Carman. 1994) . Although serum HBeAg has been identified for more than three decades. its function remains to be well elucidated (Chen. 1993. Gupta and Shafritz. 1994) . The detection of HBeAg and its corresponding antibody (anti-HBe) has clinical and epidemiolo2ical significance. Presence of HBeAg indicates actixve HBV replication with ongoing inflammatoractivity and progression of lixer disease. Patients w&ith HBeAg tend to haxe more sexvere liv-er disease than those with antiHBe. HBeAg seroconversion. indicating a transition to viral latency. is usually accompanied by biochemical and histological regression of lixer disease activity (Chen. 1993: Thomas and Carman. 1994 To compare the population-attributable risk for anti-HCV, HBsAg and HBeAg, the prevalence of anti-HCV alone, HBsAg alone and both HBsAg and HBeAg in the control group was used as the prevalence in the general population. Population-attributable risks were calculated from the odds ratios and the prevalence of these viral markers in the control group. An alpha of 0.05 was used as the indicator of statistical significance. Two-tailed P-values and 95% CIs were given when appropriate.
Results
Prevalence of anti-HCV, HBsAg, HBeAg and anti-HBe in cases and controls As shown in Table I , the prevalence of anti-HCV, HBsAg, HBeAg in HCC patients was higher than that in healthy controls (each P<0.0001). Although the prevalence of antiHBe in HBsAg-positive HCC cases was higher than that in HBsAg-positive healthy controls (P<0.0001), the prevalence of anti-HBe in HBsAg-negative patients was lower than that in HBsAg-negative healthy controls (P<0.0001). (Table II) . Moreover, the risk for developing HCC increased significantly when both markers were considered (OR=366.4). The incremental OR and the positive linear trend suggested an additive effect modification between HBsAg alone and dual HBV and HCV infection (Table II) . Multivariate analysis also demonstrated that both anti-HCV and HBsAg were independent risk factors of HCC (Table IV) . (Table IV) .
Based on a prevalence of 2.7% (10/361) for anti-HCV alone, 18.8% (68/361) for HBsAg alone and 1.9% (7/361) for both HBsAg and HBeAg carrier status in the control group as well as the odds ratio associated with these three risk factors, the estimated population-attributable risk for HCC was 11.6% for anti-HCV alone, 34.9% for HBsAg positivity alone, 15.8% for those positive for HBsAg and HBeAg and 15.6% for dual HBV and HCV infection in Taiwan. 
Disas
Taiwan is an endemic area of hepatotropic viral hepatitis (Chen, 1993; Chen et al., 1992; Tsai et al., 1990a Tsai et al., -c, 1991 Tsai et al., , 1993 Tsai et al., , 1994a Tsai et al., -h, 1995a Tsai et al., -d, 1996 . Chronic hepatitis is common. Liver cirrhosis and HCC are two of the ten leading causes of death in this country since the 1980s. The recently reported HBsAg carrier rate in the adult general population is around 15-20% (Chen et al., 1992; Chen 1993) and the prevalence of serum-anti-HDV is relatively low (2.2%) (Chen et al., 1992) . The prevalence of HBsAg (20.7%) and anti-HCV (2.7%) in our healthy controls was similar to that in community controls from the same area (Tsai et al., 1994b,e) . So we conclude that our healthy controls represent the general Taiwanese population. In this study, none of the healthy controls and only four (1.3%) out of 290 HBsAgpositive patients are positive for anti-HDV. Our result confirmed the previous observation that HDV infection was infrequent in HCC in Taiwan (Chen et al., 1984) . Chinese men who are carriers of HBsAg and/or anti-HCV have a very high risk of developing HCC that increases in the presence of cirrhosis and with advancing age (Chen, 1993; Chen et al., 1991; Lin et al., 1991; Jeng and Tsai, 1991; Tsai et al., 1994a Tsai et al., -c,ef, 1995d . In this study, the confounding effect of age and sex was adjusted by matching the controls and by multivariate analysis (Table IV) . Our results agreed with the wellestablished strong association between HBV and HCV infection and the development of HCC  Chen, 1993; Gupta and Shafritz, 1994; Tsai et a!., 1994a-J).
Chronic HBV infection can induce HCC by a variety of virus-specific mechanisms and virus-non-specific general mutagenesis mechanisms (Schirmacher et al., 1993; Gupta and Shafritz, 1994) . HBV may act as a complete carcinogen by 'initiating' the carcinogenic process through HBV-DNA integration. In the evoluation of chronic liver disease, episodic necroinflammation has been considered important not only in promoting malignant transformation (Kew and Popper, 1984; Popper et al., 1988) but also as an endogeneous cocarcinogen (Popper et al., 1988) . Chronic hepatitis and cirrhosis lead to immune-mediated permanent cell death and thus continuous regeneration that constitutes a general mutagenic mechanism (Schirmacher et al., 1993) . In this study, 84% of patients had underlying cirrhosis, whereas 16% of patients had concurrent HCV and HBV infection (Table II) . Liver disease tends to be more severe in patients with concurrent HBV and HCV infection than in patients with single HBV infection (Tsai et al., 1993; 1995b ,c, 1996 . Such chronic liver disease may also cause episodic necroinflammation. Thus, in hepatotropic virus-associated HCC, such a virus-non-specific mechanism should be taken into consideration. This may explain the additive effect of both viruses as risk factors for HCC. However, this observation warranted further evaluation, as the number of subjects with both markers in the control group was small.
As shown in Table I al., 1993; Gupta and Shafritz, 1994) .
In this study, by using a more formal epidemiological approach, we are trying to assess whether HBeAg is an independent risk factor for HCC. Regardless of concurrent HBV and HCV infection or HBV infection alone, our results indicated that the HBeAg-positive rate is significantly higher among HCC patients compared with controls (Table I) (Chen, 1993; Gupta and Shafritz, 1994) . It is unknown at present whether HBeAg increase HCC risk through causing chronic necroinflammation in the liver.
Although HBeAg may represent active HBV replication, HBV-DNA may be a better marker of ongoing viral replication (Chen 1993, Gupta and Shafritz, 1994) . AntiHBe/HBV-DNA-positive patients, with or without precore mutant, may have active liver disease and progress to HCC (Raimondo et al., 1991; Chen, 1993; Thomas and Carman, 1994) . This may explain, at least in part, the higher odds ratio in anti-HBe/HBsAg-positive patients with HCC (Table  I) . As we have not detected HBV-DNA in this study, this hypothesis awaits further study. Moreover, co-infection with other hepatotropic viruses in anti-HBe/HBsAg-positive patients may influence the magnitude of the risk for HCC.
In this study we address the evidence at a population level for the additive and independent effect of HBeAg, although of a lesser magnitude than HBsAg, on the development of HCC. As this is a case-control study, the limitation of a retrospective study for examining aetiology should be kept in mind even though it can be argued that the role of HBV in the aetiology of HCC is well enough known that the chronology of exposure (HBsAg and HBeAg) and outcome (HCC) is unlikely to be seriously in doubt. In conclusion, there is an additive and independent effect modification between HBeAg and HBsAg on the development of HCC.
